Abstract
The retinoblastoma protein (pRB) is encoded by the RB1 gene whose promoter contains several putative binding sites for ICBP90 (Inverted CCAAT box Binding Protein of 90 kDa), a transcriptional regulator of the topoisomerase IIα gene. ICBP90 has two consensus binding sites for pRB in its primary sequence. Here, we show that pRB and ICBP90 co-immunoprecipitate in cell extracts of proliferating human lung fibroblasts and of proliferating or confluent Jurkat cells. GST pull-down assays and immunocytochemistry, after cell synchronization in late G1 phase, confirmed this interaction. Overexpression of ICBP90 induces downregulation of pRB expression in lung fibroblasts as a result of mRNA decrease. DNA chromatin immunoprecipitation experiment shows that ICBP90 binds to the RB1 gene promoter under its methylated status. Overexpression of ICBP90 increases the S and G2/M phase cell fractions of serum-starved lung fibroblasts as assessed by flow cytometry analysis and increases topoisomerase IIα expression. Together, these results show that ICBP90 regulates pRB at the protein and gene transcription levels, thus favoring the entry into the S phase of the cells. We propose that ICBP90 overexpression, found in cancer cells, is involved in the altered checkpoint controls occurring in cancerogenesis.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Accession codes
Accessions
GenBank/EMBL/DDBJ
References
Almasan A, Yin Y, Kelly RE, Lee EY, Bradley A, Li W, Bertino JR and Wahl GM . (1995). Proc. Natl. Acad. Sci. USA, 92, 5436–5440.
Angus SP, Fribourg AF, Markey MP, Williams SL, Horn HF, DeGregori J, Kowalik TF, Fukasawa K and Knudsen ES . (2002). Exp. Cell Res., 276, 201–213.
Arima Y, Hirota T, Bronner C, Mousli M, Fujiwara T, Niwa S, Ishikawa H and Saya H . (2004). Genes Cells, 9, 131–142.
Bhattacharya S, Garriga J, Calbo J, Yong T, Haines DS and Grana X . (2003). Oncogene, 22, 2443–2451.
Betticher DC, White GR, Vonlanthen S, Liu X, Kappeler A, Altermatt HJ, Thatcher N and Heighway J . (1997). Int. J. Cancer, 74, 556–562.
Bonapace IM, Latella L, Papait R, Nicassio F, Sacco A, Muto M, Crescenzi M and Di Fiore PP . (2002). J. Cell Biol., 157, 909–914.
Bronner C, Hopfner R and Mousli M . (2002). Anticancer Res., 22, 605–612.
Chan HM, Smith L and La Thangue NB . (2001). Oncogene, 20, 6152–6163.
Chen PL, Riley DJ, Chen Y and Lee WH . (1996). Genes Dev., 10, 2794–2804.
Cheng CH and Kuchta RD . (1993). Biochemistry, 32, 8568–8574.
Christman JK . (2002). Oncogene, 21, 5483–5495.
Citterio E, Papait R, Nicassio F, Vecchi M, Gomiero P, Mantovani R, Di Fiore PP and Bonapace IM . (2004). Mol. Cell. Biol., 24, 2526–2535.
Coppola JA, Lewis BA and Cole MD . (1990). Oncogene, 5, 1731–1733.
Dyson N . (1998). Genes Dev., 12, 2245–2262.
Endo T and Goto S . (1992). J. Biochem. (Tokyo), 112, 427–430.
Fan S, Yuan R, Ma YX, Xiong J, Meng Q, Erdos M, Zhao JN, Goldberg ID, Pestell RG and Rosen EM . (2001). Oncogene, 20, 4827–4841.
Fang X, Jin X, Xu HJ, Liu L, Peng HQ, Hogg D, Roth JA, Yu Y, Xu F, Bast Jr RC and Mills GB . (1998). Oncogene, 16, 1–8.
Gonzalez-Gomez P, Bello MJ, Alonso ME, Arjona D, Lomas J, de Campos JM, Isla A and Rey JA . (2003). Br. J. Cancer, 88, 109–114.
Grana X, Garriga J and Mayol X . (1998). Oncogene, 17, 3365–3383.
Hickman ES, Moroni MC and Helin K . (2002). Curr. Opin. Genet. Dev., 12, 60–66.
Hong FD, Huang HJ, To H, Young LJ, Oro A, Bookstein R, Lee EY and Lee WH . (1989). Proc. Natl. Acad. Sci. USA, 86, 5502–5506.
Hopfner R, Mousli M, Oudet P and Bronner C . (2002). Anticancer Res., 22, 3165–3170.
Hopfner R, Mousli M, Jeltsch JM, Voulgaris A, Lutz Y, Marin C, Bellocq JP, Oudet P and Bronner C . (2000). Cancer Res., 60, 121–128.
Kaelin WG . (1997). Cancer Invest., 15, 243–254.
Kaelin WG . (1999). Bioessays, 21, 950–958.
Macaluso M, Cinti C, Russo G, Russo A and Giordano A . (2003). Oncogene, 22, 3511–3517.
Meerson A, Milyavsky M and Rotter V . (2004). FEBS Lett., 559, 152–158.
Momparler RL . (2003). Oncogene, 22, 6479–6483.
Mousli M, Hopfner R, Abbady A, Monté D, Jeanblanc M, Oudet P, Louis B and Bronner C . (2003). Br. J. Cancer, 89, 120–127.
Muto M, Kanari Y, Kubo E, Takabe T, Kurihara T, Fujimori A and Tatsumi K . (2002). J. Biol. Chem., 277, 34549–34555.
Nakamura M, Yonekawa Y, Kleihues P and Ohgaki H . (2001). Lab. Invest., 81, 77–82.
Nielsen SJ, Schneider R, Bauer UM, Bannister AJ, Morrison A, O'Carroll D, Firestein R, Cleary M, Jenuwein T, Herrera RE and Kouzarides T . (2001). Nature, 412, 561–565.
Pradhan S and Kim GD . (2002). EMBO J., 21, 779–788.
Richon VM, Rifkind RA and Marks PA . (1992). Cell Growth Differ., 3, 413–420.
Roncalli M, Bosari S, Marchetti A, Buttitta F, Bossi P, Graziani D, Peracchia A, Bonavina L, Viale G and Coggi G . (1998). Lab. Invest., 78, 1049–1057.
Simpson DJ, Frost SJ, Bicknell JE, Broome JC, McNicol AM, Clayton RN and Farrell WE . (2001). Carcinogenesis, 22, 1149–1154.
Simpson DJ, Hibberts NA, McNicol AM, Clayton RN and Farrell WE . (2000). Cancer Res., 60, 1211–1216.
Slack RS, Hamel PA, Bladon TS, Gill RM and McBurney MW . (1993). Oncogene, 8, 1585–1591.
Strobeck MW, Fribourg AF, Puga A and Knudsen ES . (2000a). Oncogene, 19, 1857–1867.
Strobeck MW, Knudsen KE, Fribourg AF, DeCristofaro MF, Weissman BE, Imbalzano AN and Knudsen ES . (2000b). Proc. Natl. Acad. Sci. USA, 97, 7748–7753.
Trotzier MA, Bronner C, Bathami K, Mathieu E, Abbady AQ, Jeanblanc M, Muller CD, Rochette-Egly C and Mousli M . (2004). Biochem. Biophys. Res. Commun., 319, 590–595.
Unoki M, Nishidate T and Nakamura Y . (2004). Oncogene, 23, 7601–7610.
Vasquez RJ, Howell B, Yvon AM, Wadsworth P and Cassimeris L . (1997). Mol. Cell. Biol., 8, 973–985.
Wade PA . (2001). Hum. Mol. Genet., 10, 693–698.
Walker GJ, Flores JF, Glendening JM, Lin AH, Markl ID and Fountain JW . (1998). Genes Chromosomes Cancer, 22, 157–163.
Wang G, Miskimins R and Miskimins WK . (2000). Exp. Cell Res., 254, 64–71.
Wood A, Krogan NJ, Dover J, Schneider J, Heidt J, Boateng MA, Dean K, Golshani A, Zhang Y, Greenblatt JF, Johnston M and Shilatifard A . (2003). Mol. Cell, 11, 267–274.
Young AP and Longmore GD . (2004). Oncogene, 23, 2587–2599.
Zhang HS and Dean DC . (2001). Oncogene, 20, 3134–3138.
Zhang HS, Postigo AA and Dean DC . (1999). Cell, 97, 53–61.
Zhang Y . (2003). Genes Dev., 17, 2733–2740.
Acknowledgements
The work was supported by the association Ligue contre le Cancer, Comité du Haut-Rhin.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Jeanblanc, M., Mousli, M., Hopfner, R. et al. The retinoblastoma gene and its product are targeted by ICBP90: a key mechanism in the G1/S transition during the cell cycle. Oncogene 24, 7337–7345 (2005). https://doi.org/10.1038/sj.onc.1208878
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1208878
Keywords
This article is cited by
-
UHRF1 overexpression promotes osteosarcoma metastasis through altered exosome production and AMPK/SEMA3E suppression
Oncogenesis (2022)
-
Niacin stimulates EPH4EV mammary epithelial cell proliferation and mammary gland development in pubertal mice through activation of AKT/mTOR and ERK1/2 signaling pathways
Cell and Tissue Research (2021)
-
UHRF1 depletion and HDAC inhibition reactivate epigenetically silenced genes in colorectal cancer cells
Clinical Epigenetics (2019)
-
Activated MEK/ERK Pathway Drives Widespread and Coordinated Overexpression of UHRF1 and DNMT1 in Cancer cells
Scientific Reports (2019)
-
Signalling pathways in UHRF1-dependent regulation of tumor suppressor genes in cancer
Journal of Experimental & Clinical Cancer Research (2016)